STUDY GOALS AND OBJECTIVES
BCC Research’s goal for this study is to provide a comprehensive analysis of the sequencing industry by examining all parts of the sequencing value chain. This includes sequencing sample preparation reagents and kits, instruments and consumables, bioinformatics and services. BCC Research examined the markets for these products and services for the years 2010, 2011 and 2016.
This report’s particular objective is to characterize and quantify the DNA sequencing markets by product type, platform, customer type, value chain position, analysis type and geography.
Segments of the sequencing applications market that will provide substantial future growth opportunities for industry participants include consumer and diagnostic sequencing services, bioinformatics, sequence enrichment, benchtop NGS sequencers and consumables, and emerging sequencing instruments.
This report’s main objective is to present a comprehensive discussion of DNA sequencing technologies, industry structure, key applications, major sequencing initiatives, global markets, patent status and sequencing companies. This discussion will assist life science companies in strategic planning to meet the challenges and opportunities of this dynamic industry.
REASONS FOR DOING THE STUDY
The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome. A significant outcome of the HGP was improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies).
Beginning in 2005, new sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. Opportunities emerged in sequencing workflow, instrumentation and services. The new sequencing industry is dynamic, with multiple competitors, technologies and market applications. Based on these market and technology dynamics, it is timely to examine the future DNA sequencing markets.
Ongoing advances in nanotechnology, microfluidics, imaging, enzymology and bioinformatics are revolutionizing many life science fields, as well as providing novel platforms for sequencing. At the same time, there is a growing market demand for analyzing the human genome with the goal of understanding how genetic variation relates to disease. The genetic analysis industry seeks to meet these needs with an array of tools, including microarrays, biochips, real-time polymerase chain reaction (RT-PCR) and DNA sequencing instruments.
The latest sequencing technologies compete with traditional genetic analysis tools, and this report examines this trend and its significance for companies supplying DNA sequencing products and services.
New generations of DNA sequencing technologies will continue to affect the dynamics of this industry and create novel market opportunities. This report analyzes these trends and their impact on the future markets for DNA sequencing products and services.
Given the rapid growth of this industry, it is timely to gain an understanding of these technological and competitive forces and their impact on the genetic analysis markets.
This report reviews the major sequencing technologies, including Sanger, next-generation and emerging sequencing platforms. It takes a comprehensive view of the industry and examines the markets for the entire sequencing value chain, including sample preparation, sequencing instruments and consumables, bioinformatics and sequencing services. Market growth driving forces and market sizes are reviewed. Market size information for 2010 and 2011 is provided, along with market forecasts for the period from 2011 through 2016.
BCC Research analyzes the sequencing industry dynamics, including competitors in the major market segments and the recent acquisitions and strategic alliances.
The report reviews the major global sequencing projects funded by governments and industry consortia. Sequencing patents are also reviewed.
This study will be of particular interest to life science research tools suppliers, as well as pharmaceutical, diagnostics, nanotechnology, bioinformatics, semiconductor and biotechnology companies. It will also be valuable to companies seeking to benefit from genome sequencing projects, microarray companies seeking an entry into the sequencing market, informatics companies who wish to expand their market reach and in vitro diagnostics companies who want to add sequencing platforms to their portfolios.
SCOPE AND FORMAT
The study scope includes Sanger, next-generation and emerging sequencing technologies. The markets for sample preparation products, sequencing instruments and consumables, bioinformatics and sequencing services are given for 2010 and 2011, and also forecast through 2016.
BCC examines the sequencing industry structure for the key market segments, as well as strategic alliances and acquisitions and sequencing patents. The strategies of the main sequencing companies are discussed. The main sequencing services markets are described, including diagnostics, consumer, research and development (R&D) and applied.
BCC provides information for global markets, including North America, Europe and Asia-Pacific. Specific country forecasts include the U.S., the U.K., Germany, China and Japan.
BCC surveyed key users and producers in each of the market applications that will be commercially important during the next five years: research, pharma, biotech, applied, clinical diagnostics and consumer genomics. Based on primary and secondary market analysis, this report projects the future applications of sequencing platforms and forecasts global market sizes for 2011 through 2016.
The sequencing market is analyzed by technology, product type, application, customer, analysis type, geographic region and genome type, with forecasts of market demand from 2011 through 2016. The report analyzes which applications and analyses will be important to the future of DNA sequencing, as well as the customer groups that will be consumers of the technologies. The impact on the growth of sequencing by other genetic analysis technologies such as microarrays is analyzed.
BCC surveyed leading DNA sequencing, biotechnology and nanotechnology companies, as well as core sequencing facilities and laboratories, to obtain data for this study. Research tools, drug, biotechnology and nanotechnology firms, and leading life science research institutions were included. In addition, data were compiled from secondary sources, including industry, trade and government resources.
John Bergin has written previous BCC Research biotechnology reports titled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-Chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; Synthetic Biology: Emerging Global Markets; and Biologic Imaging Reagents: Technologies and Global Markets. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company and has held executive management positions with a nanotechnology company. Mr. Bergin holds a B.S. Chemistry, a M.S. Biotechnology and a Masters of Business Administration.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Subscribe to any of BCC Research’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for its well-known conferences.
- Request additional information on any BCC research product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.